

Test Report: EN 14476 2013 Chemical disinfectants and antiseptics - Virucidal quantitative suspension test for chemical disinfectants and antiseptics used in human medicine - Test method and requirements (phase 2/step 1)

Test Laboratory

BluTest Laboratories Ltd

Robertson Incubator (Level 4)
Robertson Building
56 Dumbarton Road
Glasgow
UK - G11 6NU

Identification of sample

Name of the product	GS24
Batch number	NA
Client	Goldshield Technologies
Project Code	BT-GLD-02
Date of Delivery	11-Jun-15
Storage conditions	Ambient temp, darkness
Active substances	6 months

Test Method and its validation

Method	1 part interfering substance + 1 part virus suspension + 8 parts biocide were mixed and incubated at the indicated contact temperature for the indicated contact times. Assays were validated by a cytotoxicity control, interference control, neutralization control and a formaldehyde internal standard.
--------	---

Neutralizer	Dilution-neutralization/gel filtration; Dulbecco's modified Eagles medium + 5.0% v/v foetal bovine serum at 4°C
-------------	---

Experimental Conditions

Period of analysis	28-Jul-15 to 12-Aug-15
Product diluent used	Sterile water
Product test concentrations	5.00%(v/v) 50.00%(v/v) 80.00%(v/v)
Appearance product dilutions	N/A
Contact time (mins)	5 minutes ± 10s
Test temperature	20°C ± 1°C
Interfering substance	0.3g/l V/V bovine albumin
Stability of mixture	6 months
Temperature of incubation	37°C ± 1°C + 5% CO ₂

Identification of strains

Respiratory syncytial virus ATCC VR-26 Long strain/Hep 2 cells

Ebola virus

Order: Mononegavirales
Family: Filoviridae
Genus: Ebolavirus
Species: Ebola virus

Respiratory syncytial virus

Mononegavirales
Paramyxoviridae
Pneumovirus
Human respiratory syncytial virus

Source: International Committee on the Taxonomy of Viruses (2013 update).

A virus is a member of the order Mononegavirales if:

its genome is a linear, nonsegmented, single-stranded, non-infectious RNA of negative polarity; possesses inverse-complementary 3' and 5' termini; is not covalently linked to a protein

its genome has the characteristic gene order 3'-UTR–core protein genes–envelope protein genes–RNA-dependent RNA polymerase gene–5'-UTR

it produces 5–10 distinct mRNAs from its genome via polar sequential transcription from a single promoter located at the 3' end of the genome; mRNAs are 5' capped and polyadenylated


it replicates by synthesizing complete antigenomes

it forms infectious helical ribonucleocapsids as the templates for the synthesis of mRNAs, antigenomes, and genomes


it encodes an RNA-dependent RNA polymerase (RdRp) that is highly homologous to those of other mononegaviruses

it forms enveloped virions with a molecular mass of $300\text{--}1,000 \times 10^6$; an S20W of $550\text{--}1,045$; and a buoyant density in CsCl of $1.18\text{--}1.22 \text{ g/cm}^3$

Easton, C. R.; Pringle (2011), "Order Mononegavirales", in King, Andrew M. Q.; Adams, Michael J.; Carstens, Eric B. et al., Virus Taxonomy—Ninth Report of the International Committee on Taxonomy of Viruses, London, UK: Elsevier/Academic Press, pp. 653–657, ISBN 978-0-12-384684-6



Ebola virus



RSV

PROTOCOL SUMMARY

The basic virucidal efficacy test is set up with three concentrations of disinfectant and a 5 minute contact time. Virus is exposed to disinfectant in 24-well plates, then neutralized, serially diluted and virus titred in 96-well tissue culture plates to determine the tissue culture infectious dose₅₀ (TCID₅₀) of surviving virus. TCID₅₀ is determined by the method of Karber¹.

Cytotoxicity control

The neutralized disinfectant is measured for its effects on the host cells used to propagate the virus, to determine the sensitivity of the assay.

Interference control

The end point titration of the virus is exposed to three different sub-lethal concentrations of neutralized disinfectant to measure the effect of sub-lethal concentrations of disinfectant on virus infectivity in relation to the titre achieved on untreated cells.

Disinfectant suppression control

Virus is added to the highest concentration of disinfectant and then the mixture immediately removed and neutralized. The neutralized virus titre is then determined to assess the efficiency of the neutralization procedure.

Virus recovery control

Virus titre is determined for virus in contact with sterile hard water at t=0, t = 5 and at t =60. The virus titre after 5 minutes is then compared to the recovery of disinfectant-treated virus to measure the log reduction in virus titre. The virus titre at 60 minutes is compared to the reference virus inactivation control.

Reference virus inactivation control

Virus is exposed to 0.07% W/V formaldehyde and the recovery of virus determined by TCID₅₀ after 5, 15, 30 and 60 minutes, in order to assess that the test virus has retained reproducible biocide resistance. In addition, the formaldehyde cytotoxicity of neutralized formaldehyde is determined, to measure assay sensitivity.

1Kärber, G.: Beitrag zur Kollektiven Behandlung Pharmakologischer Reihenversuche. Arch. Exp. Path. Pharmak. 162 (1931): 480-487.

Respiratory Syncytial Virus ATCC VR-26 Long strain. A surrogate for Ebola virus.

SOP 10000 V02 EN14476 Suspension test results for the efficacy of GS24, BT-GLD-02 from Goldshield Technologies against RSV

Exposure Time	Virus Recovery 0 min		Virus Recovery 5 min		Cytotoxicity		Disinfectant Suppression		5.00% (v/v)		50.00% (v/v)		80.00% (v/v)	
	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml
t = 5	5.17	4.68E+06	5.17	4.68E+06	2.00	3.16E+03	3.33	6.76E+04	4.00	3.16E+05	1.00	3.16E+02	2.00	3.16E+03
		4.68E+06		4.68E+06		3.16E+03		6.76E+04		3.16E+05		3.16E+02		3.16E+03
log		6.67		6.67		3.50		4.83		5.50		2.50		3.50
log difference								1.84		1.17		4.17		3.17

Summary table of results of virucidal activity against RSV under clean conditions for GS24, BT-GLD-02 from Goldshield Technologies

Product:	Interfering substance	Concentration	Level of cytotoxicity	lg TCID ₅₀					>4 lg reduction after .. Min
				0 min	5 min	Y min	Z min	60 min	
GS24									
	0.3 g/l bovine albumin	80.00% (v/v)	3.50	6.67	3.50	n.a.	n.a.	n.a.	>5
		50.00% (v/v)	3.50	6.67	2.50	n.a.	n.a.	n.a.	<5
		5.00% (v/v)	3.50	6.67	5.50	n.a.	n.a.	n.a.	>5
	3.0g/l bovine albumin	n.a.	3.50	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
		n.a.	3.50	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
		n.a.	3.50	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Formaldehyde	PBS	0.7% (w/v)	1.50	6.67	5.50	3.83	2.83	2.50	60
Virus Control		n.a.	n.a.	6.67	6.67	n.a.	n.a.	6.67	n.a.

Control Data

Control Data for:		BT-GLD-02												
Stock Virus (TCID ₅₀)		6.33	6.76E+07											
Formaldehyde reference inactivation control														
Exposure time	Virus recovery 0 min		Virus recovery 60 min		Cytotoxicity		0.07% Formaldehyde							
	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	5		15		30		60	
60 min	5.17	4.68E+06	5.17	4.68E+06	0.00	3.16E+01	4.00	3.16E+05	2.33	6.76E+03	1.33	6.76E+02	1.00	3.16E+02
		4.68E+06		4.68E+06		3.16E+01		3.16E+05		6.76E+03		6.76E+02		3.16E+02
log		6.67		6.67		1.50		5.50		3.83		2.83		2.50
log difference								1.17		2.84		3.84		4.17
No Column Control				Interference control										
		Virus Recovery				Virus dilution		Cytotoxicity dilution						
		30 min						-1	-2	-3	Mock			
		raw data	TCID ₅₀ /ml					0	3	3	3			
		5.00	3.16E+06					0	3	3	3			
			3.16E+06					0	0	0	0			
			6.50	PASS								PASS		

CONCLUSION

Verification of the methodology

A test is only valid if the following criteria are fulfilled:

- a) Test virus suspension has at least a concentration which allows the determination of a 4 log₁₀ reduction of the virus titre.
- b) Detectable titre reduction is at least 4 log₁₀.
- c) Difference of the logarithmic titre of the virus control minus the logarithmic titre of the test virus in the reference inactivation test is between – 0.5 and – 2.5 after 30 min and between – 2 and – 4.5 after 60 min for virus.
- d) Cytotoxicity of the product solution does not affect cell morphology and growth or susceptibility for the test virus in the dilutions of the test mixtures which are necessary to demonstrate a 4 log reduction of the virus.
- e) The interference control result does not show a difference of < 1.0 log₁₀ of virus titre in comparison to the virus recovery control; dilutions of disinfectant to sub-acute levels did not interfere in the generation of viral cytopathic effect.
- e) Neutralisation validation. This is called the disinfectant suppression test in this protocol. The difference for virus is slightly elevated indicating rapid irreversible virucidal activity of the disinfectant by dilution at a concentration of X% v/v.
- f) A difference of <0.5 log₁₀ is not observed between virus recovered directly from the virus recovery control at 60 minutes and virus from the same control recovered through an Illustra Microspin S-400 HR column

According to EN 14476 2013, GS24 **POSSESSES VIRUCIDAL** activity at a concentration of **80.00 % V/V** of the working concentration as tested after **5 MINUTES** at **20°C** under **CLEAN** conditions (0.3 g/l bovine albumin against **Respiratory Syncytial Virus ATCC VR-26 Long strain/Hep 2 cells, a surrogate for Ebola virus.**

Signed



Dr Chris Woodall, Director
BluTest Laboratories Ltd
Glasgow, UK
Date: 18 August 2015

DISCLAIMER

The results in this test report only pertain to the sample supplied.

BluTest (BT) has performed the testing detailed in this report using reasonable skill and care and has used reasonable endeavours to carry out the testing in accordance with an EN 14476 protocol. All forecasts, recommendations and results contained in this report are submitted in good faith. However, other than as expressly set out in this report, no warranty is given (i) in relation to the testing or the use(s) to which any results or deliverables produced in the course of the testing are or may be put by the Client or their fitness or suitability for any particular purpose or under any special conditions notwithstanding that any such purpose or conditions may have been made known to BT or (ii) that the intended results or deliverables from the testing can be achieved or (iii) that the Client can freely make use of the results or the deliverables without infringing any third party intellectual property rights and the Client will be deemed to have satisfied itself in this regard. BT shall have no liability (which is hereby excluded to the fullest extent permissible by law) in respect of any loss, liability or damage, including without limitation any indirect and/or consequential loss such as loss of profit or loss of business, market or goodwill, that the Client may suffer directly or indirectly as a result of or in connection with: (i) the performance of the testing; (ii) the use of any materials, samples or other information provided by the Client for use in the testing; and (iii) the Client's reliance upon or use of any results or deliverables provided as part of the testing.